Hansoh Pharmaceutical Advances Schizophrenia Treatment with HS-10509 Clinical Trial Approval
Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials...
HKG: 3692
GSK Secures Exclusive Rights to Hansoh’s ADC Candidate HS-20093 in New Licensing Deal
GlaxoSmithKline (GSK; NYSE: GSK), a major UK pharmaceutical company, has entered into its second licensing...
Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules
Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...
Hansoh Pharmaceutical’s HS-10511 Tablets for Hypertrophic Cardiomyopathy Cleared for Clinical Trials
Hansoh Pharmaceutical (HKG: 3692) has announced that its affiliated company’s self-developed Class 1 new drug,...
Hansoh Pharmaceutical and GSK Ink Global Licensing Deal for Innovative ADC HS-20089
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20105 Clinical Study in Solid Tumors
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a China-based pharmaceutical company, has announced that it...
Hansoh Pharmaceutical Receives NMPA Approval for Generic Ofev (Nintedanib)
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received marketing...
Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...
Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and...
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Hansoh Pharmaceutical’s Ibrexafungerp NDA Accepted for Review by China’s NMPA for VVC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that the National Medical Products...
Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case
Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against...
Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical
UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone...
Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment
The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...
Hansoh Pharmaceutical Gets NMPA Approval for HS-10518 Clinical Study in Endometriosis Pain
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....
Hansoh’s HS-10517 Greenlit for COVID-19 Clinical Study by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs
The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...
Biocytogen and Hansoh Enter Antibody Collaboration and Licensing Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an antibody collaboration, assignment, and exclusive license...